NCT07280936 A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses
| NCT ID | NCT07280936 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Beijing Suncadia Pharmaceuticals Co., Ltd |
| Condition | Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 124 participants |
| Start Date | 2026-01-05 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 124 participants in total. It began in 2026-01-05 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial. This study consists of two parts: the single-dose escalation study (SAD) in healthy subjects and the multiple-dose escalation study (MAD) in obese patients.
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily sign the informed consent form prior to any study-related activities, understand the procedures and methods of the study, and agree to complete this study in strict accordance with the clinical study protocol; 2. Males or females aged 18-55 years (inclusive); 3. Subjects who are generally healthy as judged by the investigator based on medical history, vital signs, physical examination, laboratory tests, and electrocardiogram (ECG); 4. At screening, 19.0 ≤ BMI ≤ 23.9 kg/m2 (inclusive) for Part I or 28.0 ≤ BMI ≤ 35.0 kg/m2 (inclusive) for Part II. Exclusion Criteria: 1. During screening, electrocardiogram (ECG) indicated that QTcF\>450 ms in males and QTcF\> 470 ms in females, as well as other abnormal ECG and vital signs that were judged by the researchers to have clinical significance; 2. There are endocrine diseases or medical histories that may significantly affect body weight during screening (such as Cushing's syndrome, diabetes, hypothyroidism or hyperthyroidism, etc.); 3. There is a history or family history of medullary thyroid carcinoma, multiple endocrine adenomatosis type 2, or a history of pancreatitis or symptomatic gallbladder disease; 4. Other clinical findings within 12 months prior to screening that show clinical significance in the following diseases (including but not limited to gastrointestinal, kidney, liver, nervous, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases); 5. Use of prescription drugs (excluding topical eye/nasal drops and creams without systemic exposure risk), over-the-counter drugs, food supplements, vitamins and Chinese herbal medicines (excluding conventional vitamins) within two weeks prior to screening; 6. Having undergone gastrointestinal surgery that may cause malabsorption before screening, or having taken drugs that directly affect gastrointestinal peristalsis for a long time. For example: having undergone bariatric surgery or procedures (such as gastric banding), or having used weight-reducing drugs (including but not limited to orlistat) within 3 months before administration, or having a weight change of more than 10% within 3 months before administration; 7. Those who have a history of drug abuse in the past five years or have used drugs in the three months prior to the trial; Or the urine drug screening is positive; 8. Blood donation of ≥200 mL within one month prior to screening; Or those who have donated ≥400 mL of blood or lost ≥400 mL of blood within 3 months prior to screening due to trauma or major surgical operations; 9. Inability to tolerate venipuncture for blood collection or fainting at the sight of needles and blood; 10. There are special dietary requirements and they cannot follow the uniform diet; 11. Subjects who the researchers consider to have other factors that make them unsuitable for participating in this trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07280936 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07280936 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07280936 currently recruiting?
Yes, NCT07280936 is actively recruiting participants. Contact the research team at zi.ye@hengrui.com for enrollment information.
Where is the NCT07280936 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT07280936 clinical trial?
NCT07280936 is sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. The trial plans to enroll 124 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.